Severe hypoglycemia is an emergency, and older glucagon rescue kits required mixing a powder under extreme time pressure. Zegalogue (dasiglucagon) removed that step with a stable, ready-to-use formulation.
Supplied as an autoinjector or prefilled syringe requiring no reconstitution, Zegalogue raises blood glucose by prompting the liver to release stored glucose, acting within minutes of injection. The glucagon analog is approved for severe hypoglycemia in people with diabetes aged 6 years and older.
Zegalogue competes in a rescue-glucagon market that has shifted decisively toward ready-to-use devices, and it faces no generic competition. Its analog stability and device format are the key differentiators for tracking rescue therapy adoption and formulary positioning.
